腹主动脉、胸腹主动脉及胸主动脉瘤腔内修复术的兴起
该研究基于2004至2019年全国住院患者样本,分析腹主动脉瘤、胸腹主动脉瘤及胸主动脉瘤的入院与修复趋势。结果显示完整腹主动脉瘤修复与破裂腹主动脉瘤入院均显著减少,各部位动脉瘤的腔内技术使用率均上升,2019年89%的完整腹主动脉瘤修复采用腔内方式。
要点
- 2004至2019年完整腹主动脉瘤修复与破裂腹主动脉瘤入院均显著减少。
- 完整腹主动脉瘤修复中腔内修复占比从45%升至66%,复杂腔内修复从0%升至23%。
- 2019年89%的完整腹主动脉瘤修复采用腔内修复(EVAR或cEVAR)。
核心结论
- 2004至2019年完整腹主动脉瘤修复与破裂腹主动脉瘤入院均显著减少,各部位动脉瘤的腔内修复使用率均上升。
- 2019年89%的完整腹主动脉瘤修复采用腔内修复,复杂腔内修复占完整腹主动脉瘤修复的23%。
- 腔内修复现用于大多数完整主动脉瘤修复,需长期数据评估其耐久性。
研究设计与样本
- 研究识别2004至2019年全国住院患者样本中因破裂主动脉瘤入院及因完整主动脉瘤修复的所有患者。
- 共识别腹主动脉瘤患者715,570例(完整修复87%,破裂入院13%)。
- 共识别胸腹主动脉瘤患者27,443例(完整80%,破裂20%)。
- 共识别升主动脉、主动脉弓或降主动脉胸主动脉瘤患者141,651例(完整90%,破裂10%)。
主要发现
- 完整腹主动脉瘤修复从41,060例降至34,215例(P < .01),破裂腹主动脉瘤入院从7,175例降至4,625例(P = .02)。
- 完整腹主动脉瘤修复中EVAR占比从45%升至66%(P < .01),破裂腹主动脉瘤修复中EVAR占比从10%升至55%(P < .01)。
- 2010至2019年完整腹主动脉瘤修复中cEVAR占比从0%升至23%(P < .01),破裂腹主动脉瘤修复中cEVAR占比从0%升至14%(P < .01)。
- 完整腹主动脉瘤EVAR后死亡率降低29%(2004年0.73%至2019年0.52%,P < .01),OAR后死亡率升高16%(4.4%至5.1%,P < .01)。
- 完整胸腹主动脉瘤修复从1,435例增至1,640例(P = .055),cEVAR占比从3.8%升至72%(P = .055)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
- 需长期数据评估这些手术的耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given changes in intervention guidelines and the growing popularity of endovascular treatment for aortic aneurysms, we examined the trends in admissions and repairs of abdominal aortic aneurysms (AAAs), thoracoabdominal aortic aneurysms (TAAAs), and thoracic aortic aneurysms (TAAs). METHODS: We identified all patients admitted with ruptured aortic aneurysms and intact aortic aneurysms repaired in the Nationwide Inpatient Sample between 2004 and 2019. We then examined the use of open, endovascular, and complex endovascular repair (OAR, EVAR, and cEVAR) for each aortic aneurysm location (AAA, TAAA, and TAA), alongside their resulting in-hospital mortality, over time. cEVAR included branched, fenestrated, and physician-modified endografts. RESULTS: 715,570 patients were identified with AAA (87% intact repairs and 13% rupture admissions). Both intact AAA repairs and ruptured AAA admissions decreased significantly between 2004 and 2019 (intact 41,060-34,215, P < .01; ruptured 7175-4625, P = .02). Of all AAA repairs performed in a given year, the use of EVAR increased (2004-2019: intact 45%-66%, P < .01; ruptured 10%-55%, P < .01) as well as cEVAR (2010-2019: intact 0%-23%, P < .01; ruptured 0%-14%, P < .01). Mortality after EVAR of intact AAAs decreased significantly by 29% (2004-2019, 0.73%-0.52%, P < .01), whereas mortality after OAR increased significantly by 16% (2004-2019, 4.4%-5.1%, P < .01). In the study, 27,443 patients were identified with TAAA (80% intact and 20% ruptured). In the same period, intact TAAA repairs trended upward (2004-2019, 1435-1640, P = .055), and cEVAR became the most common approach (2004-2019, 3.8%-72%, P = .055). A total of 141,651 patients were identified with ascending, arch, or descending TAAs (90% intact and 10% ruptured). Intact TAA repairs increased significantly (2004-2019, 4380-10,855, P < .01). From 2017 to 2019, the mortality after OAR of descending TAAs increased and mortality after thoracic endovascular aneurysm repair decreased (2017-2019, OAR 1.6%-3.1%; thoracic endovascular aneurysm repair 5.2%-3.8%). CONCLUSIONS: Both intact AAA repairs and ruptured AAA admissions significantly decreased between 2004 and 2019. The use of endovascular techniques for the repair of all aortic aneurysm locations, both intact and ruptured, increased over the past two decades. Most recently in 2019, 89% of intact AAA repairs, infrarenal through suprarenal, were endovascular (EVAR or cEVAR, respectively). cEVAR alone increased to 23% of intact AAA repairs in 2019, from 0% a decade earlier. In this period of innovation, with many new options to repair aortic aneurysms while maintaining arterial branches, endovascular repair is now used for the majority of all intact aortic aneurysm repairs. Long-term data are needed to evaluate the durability of these procedures.
引用
- Conroy PD, Rastogi V, Yadavalli SD, et al. The rise of endovascular repair for abdominal, thoracoabdominal, and thoracic aortic aneurysms. J Vasc Surg. 2024. PMID: 38942397. doi:10.1016/j.jvs.2024.06.165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。